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Plasma cells (PCs) are the effectors responsible for antibody (Ab)-mediated immunity.They
differentiate from B lymphocytes through a complete remodeling of their original struc-
ture and function. Stress is a constitutive element of PC differentiation. Macroautophagy,
conventionally referred to as autophagy, is a conserved lysosomal recycling strategy that
integrates cellular metabolism and enables adaptation to stress. In metazoa, autophagy
plays diverse roles in cell differentiation. Recently, a number of autophagic functions
have been recognized in innate and adaptive immunity, including clearance of intracellular
pathogens, inflammasome regulation, lymphocyte ontogenesis, and antigen presentation.
We identified a previously unrecognized role played by autophagy in PC differentiation and
activity. Following B cell activation, autophagy moderates the expression of the transcrip-
tional repressor Blimp-1 and immunoglobulins through a selective negative control exerted
on the size of the endoplasmic reticulum and its stress signaling response, including the
essential PC transcription factor, XBP-1.This containment of PC differentiation and function,
i.e., Ab production, is essential to optimize energy metabolism and viability. As a result,
autophagy sustains Ab responses in vivo. Moreover, autophagy is an essential intrinsic
determinant of long-lived PCs in their as yet poorly understood bone marrow niche. In
this essay, we discuss these findings in the context of the established biological functions
of autophagy, and their manifold implications for adaptive immunity and PC diseases, in
primis multiple myeloma.
Keywords: antibody, autophagy, endoplasmic reticulum, multiple myeloma, plasma cell, proteostasis, unfolded
protein response, XBP-1
INTRODUCTION
The biology of plasma cell (PC) differentiation is a unique model
for scientists to investigate the complex connections between
metabolism, stress, proteome plasticity, and cellular renovation. In
particular, the regulation of antibody (Ab) production is a valuable
paradigm for the molecular wirings controlling protein folding
and assembly in professional secretory cells. Moreover, the bone
marrow PC niche, which provides lifelong Ab memory, depends on
as yet incompletely understood intrinsic and environmental com-
ponents, whose derangement is instrumental to the development
of multiple myeloma.
We recently discovered an unanticipated essential function
played by autophagy during PC differentiation, disclosing new
links with endoplasmic reticulum (ER) homeostasis and Ab pro-
duction. Moreover, autophagy emerges as an intrinsic requirement
of long-lived PCs and long-term immunity (1). Scope of the
present review is to discuss the newly identified role of autophagy
in PC pathophysiology, in perspective of recently established
autophagic functions across stress biology, cell differentiation,
immunity, and cancer.
Abbreviations: Ab, antibody; Ag, antigen; EM, electron microscopy; ER, endoplas-
mic reticulum; ERAD, ER associated degradation; Ig, immunoglobulin; PC, plasma
cell; SILAC, stable isotope labeling in cell culture; SLR, SQSTM1-like receptor; TLR,
Toll-like receptor; UPR, unfolded protein response
THE STRESS OF PLASMA CELL DIFFERENTIATION
Plasma cells are the terminal effectors of adaptive immunity
endowed with the unique ability to secrete Abs capable of neutral-
izing pathogens and toxins. Upon encounter with antigens (Ags),
B cells differentiate into short-lived PCs in secondary lymphoid
organs (e.g., spleen and lymph nodes). Most of these effector cells
die within few days. In addition,T cell-dependent responses induce
the germinal center reaction, which generates a second wave of
plasmablasts, secreting high-affinity, class-switched Abs, and capa-
ble of acquiring lifelong survival in dedicated bone marrow niches.
Long-lived PCs maintain immunological memory of Ab-inducing
Ags, yielding prompt protection against pathogens and their toxic
products (2).
From a biological standpoint, PCs are professional secretory
cells dedicated for massive synthesis, assembly, and secretion of
Abs. To accomplish this mission, upon activation, B cells must
reshape their proteome. To this aim, a powerful genetic pro-
gram silences B cell identity, through the repression of genes
encoding the transcription factors Pax5 and Bcl-6, and estab-
lishes PC function, inducing the transcriptional regulators IRF4
and PRDM1/Blimp-1 (3). Early during differentiation, XBP-1, a
key ER stress transducer and transcription factor of the unfolded
protein response (UPR), drives ER expansion to augment the
folding capacity of this organelle and accommodate intensive
immunoglobulin (Ig) synthesis in the secretory pathway (4, 5).
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In addition to ER stress, other stresses are constitutive of full
gear Ab production in PCs. For example, oxidative protein folding
causes redox stress, counterbalanced by antioxidant responses (6,
7). After the blastic phase, in post-mitotic PCs, additional stress
may ensue from the impossibility of diluting damaged organelles
through cell division, as demonstrated in other non-dividing ter-
minally differentiated cells (8). We found that PCs also experi-
ence profound proteasome stress (9). Indeed, although Ig-synthetic
activity requires intense proteasome-dependent degradation of Ab
byproducts, during their differentiation short-lived PCs display
a progressive, remarkable reduction of proteasome expression,
which leads to accumulation of poly-ubiquitinated proteins, at
the expense of free ubiquitin – an additional stress referred to as
ubiquitin stress (10) – and stabilization of proapoptotic factors (11,
12). This apparently paradoxical lack of adaptation may serve as
a built-in mechanism to reduce the apoptotic threshold and limit
PC lifespan and the duration of Ab responses (13). We also noted
that PC differentiation confers exquisite sensitivity to proteasome
inhibition, rendering PCs as sensitive to proteasome inhibitors as
multiple myeloma cells, disclosing a general characteristic of PCs,
rather than a feature of malignancy (9). Attenuating general pro-
tein synthesis by the otherwise toxic agent cycloheximide reduces
proteasome sensitivity in differentiating plasmablasts, indicating
protein synthesis as a key determinant of the proteolytic burden
on proteasomes in PCs (14). Such a challenged protein homeosta-
sis (proteostasis) may explain why the first-in-class proteasome
inhibitor bortezomib reduced Ab responses (12) and attenuated
autoAb-mediated pathology in a mouse model of lupus (15).
Clearly, basic stress biology in PCs is instructive on putative targets
against PC dyscrasias (see below).
AUTOPHAGY: FROM BULK DEGRADATION TO SELECTIVE
RECYCLING
Autophagy is a highly conserved self-digestive strategy that
envelops cytoplasmic contents in a double-membrane vesicle, the
autophagosome, delivered to the lysosome (in animal cells) or to the
vacuole (in plant and yeast cells) for subsequent degradation and
recycling. The prime function of autophagy in unicellular organ-
isms is to sustain cellular metabolism in conditions of nutritional
starvation (16, 17). This metabolic role is conserved in metazoa,
where autophagy is an essential source of energetic equivalents
(18). An exemplar case,autophagy-incompetent newborn mice fail
to resist the physiologic early neonatal starvation (19). Autophagy
also provides building blocks for cellular renovation, and is cru-
cially involved in differentiation and development (18, 20). In
mammals, autophagy is essential for embryogenesis (21) and lin-
eage differentiation, as demonstrated, for example, in adipocytes,
erythrocytes, and lymphocytes (20).
By contrast with the ubiquitin–proteasome system, autophagy
has long been viewed as a bulk non-selective process, with the
only exception of chaperone-mediated autophagy. Its recently rec-
ognized capacity to ensure cellular quality control by clearing
toxic and damaged macromolecules and organelles disclosed an
unanticipated level of selectivity (22, 23). Selective autophagic
degradation has been reported for a number of endogenous
supramolecular structures: peroxisomes (pexophagy) (24), pro-
tein aggregates (aggrephagy) (25–27), ribosomes (ribophagy) (28),
mitochondria (mitophagy) (29–31), lipid droplets (lipophagy)
(32), secretory granules (zymophagy) (33), and midbody remnants
after cytodieresis (34).
To target selected cargoes, autophagy makes use of adapter pro-
teins acting as receptors. To mediate selective autophagy, these
proteins must: (i) recognize substrates via a ubiquitin-binding
activity; (ii) cross-link the cargo with the autophagic machinery
via an LC3-interacting region; and (iii) polymerize (23, 35). Ubiq-
uitination is thus used not only to convey individual proteins to the
proteasome, but also for selective recognition by autophagic recep-
tors, e.g., p62 and NBR1 during mitophagy and aggrephagy. While
the prime tag for proteasomal degradation is a chain of ubiq-
uitins covalently linked through their K48 lysine residues, K63-
linked poly-ubiquitin tags may be preferentially associated with
autophagic degradation, although additional post-translational
modifications may contribute to direct cargoes to autophagy (23).
In most cases, the ubiquitin ligases involved in autophagy remain
to be identified. Hitherto established mammalian autophagic
receptors include SQSTM1/p62, NBR1, optineurin, NDP52, and
Nix. Adaptor proteins are also being characterized, which inter-
act with autophagy receptors to recruit and assemble more Atg
proteins, so as to shape the growing autophagosome (phagophore)
around the cargo (36).
Virtually, all cellular membranes have been proposed to con-
tribute to autophagosome biogenesis. Among them, the ER is an
established membrane source for the phagophore (37). The ER
may also undergo autophagic degradation: autophagic trimming
of excess ER (reticulophagy, ER-phagy) counterbalances pharma-
cological stress-induced ER expansion in yeast (38). More recently,
a mechanism mediating both mitophagy and ER-phagy has been
described in HeLa cells (39). However, defining the physiological
significance of reticulophagy in mammals is biologically relevant.
As described below, our recent work on autophagy in PCs furthers
this view by defining ER-phagy as an essential determinant of PC
biology and Ab immunity (1).
ROLES OF AUTOPHAGY IN INNATE AND ADAPTIVE
IMMUNITY
In the immune system, autophagy serves diverse innate and adap-
tive functions, including microbe clearance, Ag presentation, and
the regulation of inflammation and lymphocyte development
(40–42). The co-optation of autophagy to destroy intracellular
microbes, i.e., xenophagy, already present in unicellular organ-
isms (43), likely represents the most ancient form of immune
defense. Xenophagy has been shown to restrict the growth of bac-
teria (L. monocytogenes, S. flexnerii, S. typhimurium) (42). The
infectious phagosome is intracellularly recognized through inter-
nal toll-like receptor (TLR) signaling (44). Then, infected cells can
promote phagosome–lysosome fusion or target cytosol-invading
bacteria for autophagic degradation (36). A number of autophagic
receptors, including SQSTM1/p62, NDP52, and optineurin, have
been shown to specifically recognize ubiquitinated bacteria within
the cytosol (23, 36), hence the idea that SQSTM1-like recep-
tors (SLRs) constitute a new family of innate pattern recogniz-
ing receptors (45). Autophagy may play additional antimicrobial
activities through SLRs, e.g., by generating microbicidal pep-
tides via incomplete digestion of ribosomal protein precursors
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during M. tuberculosis infection (46). Autophagy also mediates
viral recognition and destruction. For example, capsid proteins
of the neurotropic Sindbis virus are degraded via p62-dependent
autophagy (47).
Autophagy is also involved in the modulation of the inflamma-
tory response. In particular, autophagy may both stimulate and
inhibit the activity and output of the inflammasome. While basal
autophagy prevents inflammation, e.g., by limiting mitochondrial
generation of reactive oxygen species and the resulting inflam-
masome activation (48, 49), induction of autophagy can promote
inflammation, mediating the inflammasome-dependent uncon-
ventional release of the endogenous pyrogen, IL-1β, which in turn
can intensify autophagy (50). Autophagy may also yield negative
feedback loops to prevent destructive inflammation, e.g., moder-
ating IL-1β release by targeting inflammasomes and pro-IL-1β for
degradation (51, 52).
Autophagy also serves adaptive immune functions, including
the regulation of lymphocyte ontogenesis and homeostasis. Atg
proteins have been shown to maintain normal numbers of CD4+
and CD8+ T cells, and fetal hematopoietic stem cells (41, 53,
54). First, Atg5−/− bone marrow chimeric mice revealed defects
in T cell development and peripheral homeostasis, and impaired
activation-induced proliferation (55). Although activated T cells
require autophagy, negative controls may come into play to temper
autophagy, preventing detrimental effects. Indeed, components
of the extrinsic apoptotic cascade, namely FADD and caspase 8,
were found to limit autophagy by interacting with the Atg5–Atg12
complex, thereby sustaining viability of activated T cells (56). In
following studies, the development of mature T cells was found
to require an active negative control on the intracellular produc-
tion of reactive oxygen species, which in turn relies on efficient
mitophagy (55, 57). Such mitochondrial quality control maintains
mature naïve T cell homeostasis through Beclin-1 stabilization by
the class III phosphoinositide-3 kinase Vps34 (58, 59). Moreover,
in activated T cells, autophagy is induced to maintain ATP levels,
proliferation, and the release of cytokines (60).
Autophagy is also important for B cell development: irradiated
Rag1−/− recipients repopulated with fetal liver progenitors lacking
the essential autophagic factor Atg5 have low counts of peritoneal
B-1 B cells, due to defective transition of pro- to pre-B cells (61).
Moreover, mice with conditional deletion of Atg5 in mature B
cells (Atg5f/fCD19-Cre) show normal numbers of mature B lym-
phocytes and a normal ratio of marginal zone to follicular B cells,
but reduced maintenance of B-1a cells in the periphery (1, 61).
A number of studies have implicated autophagy in different
Ag presentation pathways. The delivery of exogenous Ags for
MHC class II presentation to CD4+ T cells has been shown to
depend on autophagy (62). Indeed, MHC class II-loading com-
partments receive continuous input from autophagosomes, and
autophagy has been shown to positively control CD4+ T cell
priming (63–65). Moreover, thymic epithelial cells deliver self Ags
to MHC class II-loading compartments through the autophagic
machinery. This task is essential to build self-tolerance, as its dis-
ruption leads to defective elimination of autoreactive T cells and
autoimmunity (66). Furthermore, autophagy has been shown to
mediate CD8+ T cell priming in vivo through cross-presentation
of phagocytosed Ags, normally routed through the MHC class II
pathway, on MHC class I (67, 68). However, autophagy is not a
universal Ag-presenting pathway, as we proved it dispensable for
presentation by B cells to cognate T cells in the germinal center
(see below) (1).
We hypothesized that autophagy may play an additional adap-
tive immune function in terminal PC differentiation, based on the
specific biology of Ab-secreting cells (9). First, PC differentiation
is expected to require a high degree of proteome plasticity. In sup-
port of this notion, we had generated quantitative evidence that
both protein translation and degradation increase remarkably in
primary activated B cells (14). Second, we had observed that such
an increased demand for protein degradation is not met by a corre-
sponding increase in proteasome capacity, which instead decreases
dramatically (11, 12, 14), and reasoned that this would call for
complementary protein degradation routes. Having the capacity
to compensate for proteasome insufficiency (69), autophagy was
an obvious candidate. Third, most, if not all, stresses experienced
by PCs are known to be relieved by autophagy (9, 22). The follow-
ing paragraphs illustrate our findings, unveiling the crucial role
served by autophagy in the differentiation, function, and viabil-
ity of PCs, required for humoral immunity, and the underlying
mechanism, linking ER homeostasis with Ig synthesis and energy
metabolism.
AUTOPHAGY SUSTAINS Ab RESPONSES AND IS ESSENTIAL
TO LONG-LIVED PCs
When we assessed overall autophagic activity in differentiating
PCs, we found strong induction of autophagy following B cell
activation, both ex vivo and in vivo. In keeping with a develop-
mental program, similar to UPR transcripts,Atg mRNAs increased
concertedly during PC differentiation. The use of GFP-LC3 trans-
genic mice revealed intense autophagy also in long-lived bone
marrow PCs (1). Encouraged by these observations, to assess the
functional relevance of autophagy in PC ontogenesis, we first
investigated Ab responses in Atg5f/fCD19-Cre mice. These mice
showed reduced IgM and IgG responses in both T-independent
and T-dependent immunization experiments, demonstrating a
positive role of autophagy in Ab responses mediated by short-
lived PCs. A parallel independent study confirmed these findings,
by showing significantly diminished Ab titers in the same mouse
model during Ag-specific immunization, parasitic infection, and
mucosal inflammation (70).
Inspired by the observation of high autophagic activity also in
long-lived PCs, we then asked whether Atg5 is required for long-
term humoral immunity, by assessing if Atg5f/fCD19-Cre mice
show defects in bone marrow PC populations. These mice had
normal bone marrow PC counts, apparently arguing against a role
for autophagy in long-lived PCs. However, the genomic quantifi-
cation of Cre-mediated deletion of Atg5 disclosed that while in
splenic B cells most Atg5 alleles had undergone Cre-dependent
recombination, bone marrow PCs displayed normal amounts of
the non-deleted allele. Hence, an efficient Darwinian selection
for autophagy-competent PCs had occurred, demonstrating that
autophagy is absolutely required to establish or maintain long-
lived PCs. Moreover, despite a normal size of the bone marrow
PC pool, Atg5f/fCD19-Cre mice revealed a defect in long-term Ab
immunity, as they had virtually absent Ag-specific long-lived PCs
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in the bone marrow 11 months after T-dependent immunization.
Altogether, the data establish autophagy as a novel determinant of
the PC memory compartment (1).
Being essential to generate class-switched and high-affinity
memory B cells and long-lived PCs, we also checked the germi-
nal center reaction in NP-CGG-immunized Atg5f/fCD19-Cre mice,
but found it normal (1). This evidence mapped the requirement of
autophagy specifically to PCs. Moreover, since the germinal center
response requires Ag presentation by B cells to cognate T cells, this
data demonstrated that autophagy is dispensable for soluble Ag
presentation in B cells, in spite of its Ag-presenting role in other
contexts (discussed above).
The above findings further our understanding of the intrin-
sic molecular competence required for PCs to achieve extended
survival in the bone marrow (2). Hitherto recognized compo-
nents of such competence comprise the chromatin modifier Aiolos
(71), the transcriptional regulators Blimp-1 (72) and XBP-1 (73),
and the anti-apoptotic molecule Mcl-1 (74). The identification of
autophagy as a novel molecular requirement of bone marrow PCs
and of long-lived humoral immunity is in keeping with its estab-
lished capacity to grant extended survival to quiescent progenitors
and highly specialized terminally differentiated cell types, such as
neurons (75).
An important matter of future investigation is the precise level
at which autophagy is required in memory PC ontogenesis, i.e., the
survival of non-resident long-lived plasmablasts, their migration
to the bone marrow, or the maintenance of resident long-lived
PCs in the medullary niche. Moreover, it would be interesting to
determine if autophagy also plays a role in maintaining the other
memory compartment of B cell immunity, i.e., non-Ig-secreting
memory B cells.
AUTOPHAGY CONTAINS PC DIFFERENTIATION AND Ab
PRODUCTION THROUGH SELECTIVE ER-PHAGY
The easiest conceivable explanation for autophagy sustaining Ab
immunity was to hypothesize it to be required for PC differentia-
tion. Confuting this hypothesis, Atg5-deficient B cells apparently
underwent normal PC differentiation (1). The exact molecular role
of autophagy in developing PCs was gaged by an unbiased com-
parison of the proteome of autophagy-competent vs. incompetent
activated B cells by stable isotope labeling in cell culture (SILAC).
Importantly, the proteome of differentiating PCs was completely
labeled in as little as 3 days upon activation, not only enabling this
approach, but also convincingly demonstrating the highest pro-
teome plasticity inherent to this differentiation program. SILAC
proteomics of Atg5−/− PCs revealed a selective and rather exclusive
expansion of the ER proteome, including Igs. An autophagic regu-
lation of the size of the ER was demonstrated by two independent
electron microscopy (EM) approaches: classical EM and an EM
cytochemistry technique designed to stain and unbiasedly quan-
tify the ER (76). Short treatment with distal autophagy inhibitors
was sufficient to increase ER proteins in wild type differentiat-
ing PCs, unveiling the first case of physiologic reticulophagy in
mammals (1).
Attesting to the functional relevance of the identified
autophagic regulation of the ER in PC differentiation, Atg5−/−
PCs had higher UPR signaling than wild type PCs, associated
FIGURE 1 | Effect of Atg5 deficiency on plasma cell differentiation and
Ab immunity. In differentiating plasma cells, autophagy limits the
expansion of the endoplasmic reticulum (ER), providing the first
physiological case of mammalian ER-phagy. As a result, Atg5−/− plasma
cells show more abundant ER than wild type counterparts and more
intense ER stress signaling (including higher expression of the essential
plasma cell transcription factor, XBP-1), which in turn enhances the
expression of the key plasma cell transcriptional regulator PRDM1/Blimp-1
and of immunoglobulins (Ig). Hence, despite increased Ig production,
autophagy-deficient plasma cells have less ATP and live a shorter life,
yielding defective Ab responses in vivo.
with higher expression of Blimp-1 and Ig transcripts, indicating
that autophagy restricts the expression of two key determinants
of PC differentiation, XBP-1 and Blimp-1, and of Igs. Providing
mechanistic insight, pharmacological ER stress in wild type differ-
entiating PCs was sufficient to increase Blimp-1 and Ig expression
beyond the putatively maximal levels associated to PC differentia-
tion. As a result, Atg5−/− PCs translated, assembled, and secreted
more Abs over time, disclosing an unsuspected regulatory cir-
cuit of PC function negatively controlled by autophagy (1, 75)
(see Figure 1). It will be important to dissect the mechanisms
underlying ER-phagy during PC differentiation.
In cellular models of protein folding diseases, autophagy has
been shown to dispose of polymeric misfolded protein aggregates
in the ER, constituting an alternative form of ER associated degra-
dation (ERAD) (77, 78). Noticeably, instead, in differentiating PCs,
autophagy does not serve a similar quality control function in
the secretory pathway, nor does it remove dysfunctional ER, as
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Atg5−/− PCs show normal Ig assembly, and do not accumulate Ig
aggregates, but rather display higher capacity in their expanded
secretory apparatus (1).
These findings imply that PCs are programed to become more
productive Ab factories than actually observed, with autophagy
acting as a physiologic brake on their differentiation and function.
How is this reconciled with the defective Ab responses mounted
by Atg5f/fCD19-Cre mice? This paradox is solved by the observa-
tion that Atg5−/− PCs have less ATP and live a shorter life than
wild type counterparts. Hence, autophagy accomplishes a sensible
trade-off between viability and function, setting Ab production to
sustainable levels (1, 75).
Can the higher Ig-secreting potential of PCs be demonstrated
in vivo? A proof-of-principle experiment was the immunization
with the T-independent hapten NP-ficoll, which, in our hands,
yielded higher anti-NP Ig titers in Atg5f/fCD19-Cre mice, despite
normal PC counts, in line with the higher secretory activity of
Atg5−/− PCs observed ex vivo. Unlike other Ags, NP-ficoll has
been shown to persist and cause continual B cell activation (79).
Hence, repeated rounds of PC differentiation may have surpassed
the otherwise dominant impact of reduced PC viability on Ab
titers, witnessing the hypersecretory effect of Atg5 deficiency at
the single PC level (1, 75).
The discovery of a novel autophagy-centered regulatory net-
work balancing PC activity and survival in vivo implies an unsus-
pected plasticity of Ab responses, potentially exploitable to tune
their duration and intensity. A number of immune signaling
molecules can regulate autophagy (41, 45), supporting this possi-
bility, and offering opportunities to search for molecular targets
to modulate Ab responses, of therapeutic use against autoimmune
diseases.
AUTOPHAGY IN MULTIPLE MYELOMA
A matter of intense scientific debate, the role of autophagy in can-
cer is complex. Genetic defects of autophagy have been linked
with tumorigenesis, establishing the notion that autophagy is a
tumor suppressive pathway (80). Oncosuppressive mechanisms
of autophagy include protection against the accumulation of
oncogenic mutations (81–83) and reactive oxygen species, mainly
through mitochondrial homeostasis, and reduction of necrosis
and local inflammation (84). While in healthy cells, autophagy
may suppress tumor initiation, established cancers may subvert
autophagy to cope with intrinsic (e.g., metabolic), environmental
(e.g., hypoxic), or pharmacological stress (e.g., induced by cyto-
toxic agents). This may explain why pharmacological inhibition of
autophagy may be beneficial against cancer, being toxic to tumor
cells and sensitizing them to chemotherapy (80, 85).
Multiple myeloma is a valuable model to investigate the role
of autophagy in cancer, especially in perspective of integrated
cancer proteostasis. Indeed, myeloma represents the paradigmatic
neoplasm responsive to proteasome inhibitors, prototypical neg-
ative proteostasis regulators, although a substantial proportion of
patients fail to respond, and resistance inevitably ensues (9, 86–
88). We demonstrated that the exquisite proteasome sensitivity
of normal and malignant PCs stems from an unfavorable ratio
between proteasome workload and overall capacity (9, 11, 12),
and termed this feature proteostenosis (13). Moreover, we found
that myelomas with the highest sensitivity to proteasome inhibi-
tion are those expressing fewer active proteasomes in spite of the
highest degradative workload, both features being causal to such
inherent vulnerability (89). Noticeably, the degradative burden is a
relatively neglected source of cellular stress, particularly in cancer
(90). In myeloma, we found that recent protein synthesis saturates
the limited capacity of the ubiquitin–proteasome system, causing
the buildup of ubiquitin conjugates, and is a crucial determinant
of proteasome stress (14). It is noteworthy that lymphoplasmocytic
lymphoma (Waldenstrom’s macroglobulinemia), another B cell can-
cer known to produce high levels of IgM, also proved vulnerable to
proteasome inhibition (91–93), and the clinical use of bortezomib
yielded encouraging results (94, 95).
Autophagy and the ubiquitin–proteasome system are inte-
grated strategies that cooperate to maintain cellular proteostasis
(69). This notion is sufficient to predict that multiple myeloma
and Waldenstrom’s macroglobulinemia may be as dependent on
autophagy as they are on the ubiquitin–proteasome system. This
prompted different laboratories to target autophagy in order
to overcome resistance to proteasome inhibitors and achieve
myeloma cell death, with controversial results. While the block-
ade of autophagy appears toxic against human myeloma lines,
the combined inhibition of the proteasome and autophagy may
be synergic or antagonistic, depending on the molecular level
of autophagic inhibition (88, 96–98). Experimental discrepancies
may be partly explained by the recent discovery of a vital cir-
cuit blocking autophagy, disclosing that deregulated autophagy
can turn maladaptive in multiple myeloma cells. In brief, human
myeloma lines depend for their survival on IRF4, which, through
a caspase 10-dependent mechanism, prevents excessive autophagy
from executing non-apoptotic myeloma cell death (99). This data
suggests that autophagy may play both adaptive and maladaptive
roles in myeloma, depending on its intensity, or its targets. A bet-
ter understanding of the basal, adaptive function of autophagy in
myeloma cells is needed to harness this pathway against cancer.
Our identification of a new homeostatic function of autophagy,
essential for the maintenance of long-lived PCs in the bone mar-
row, the normal counterpart of multiple myeloma (1, 75), prompts
to test if PC tumors are at least as dependent on autophagy for
their survival, and provides a framework for dissecting the precise
function of autophagy in normal and malignant bone marrow
PCs. The diverse homeostatic activities of autophagy in different
lineages and diseases hitherto defined suggests that PC-specific,
and possibly myeloma-specific, autophagic circuits may be iden-
tified, linking organelle homeostasis, stress responses, and energy
metabolism, to disclose new molecular therapeutic targets.
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